Arcus Biosciences

Recent news

• H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/9/26
• Rating change
  Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $41
  Market Newswire · 2026/7/23
• Rating change
  BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Raises Target Price to $29
  Market Newswire · 2026/8/3
• Rating change
  A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45
  Market Newswire · 2026/8/7
• Rating change
  Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $34
  Market Newswire · 2026/5/7
• Rating change
  Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/9/10
• Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $43
  Market Newswire · 2026/9/30
• Rating change
  LifeSci Capital Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $46
  Market Newswire · 2026/6/4
• Rating change
  Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42
  Market Newswire · 2026/8/8
• Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)
  TipRanks · 2026/9/25
• BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $29
  Market Newswire · 2026/10/5
• Rating change
  TD Cowen Initiates Arcus Biosciences(RCUS.US) With Buy Rating
  Market Newswire · 2026/9/16
• Rating change
  Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $42
  Market Newswire · 2026/8/10
• Rating change
  BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $25
  Market Newswire · 2026/4/22
• Rating change
  H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $45
  Market Newswire · 2026/7/20
• Rating change
  H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $32
  Market Newswire · 2026/6/4
• Rating change
  Truist Financial Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $35
  Market Newswire · 2026/5/19
• Rating change
  Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
  Market Newswire · 2026/7/23
• LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46
  Market Newswire · 2026/9/28
• Rating change
  Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $40
  Market Newswire · 2026/9/8

Headlines are aggregated automatically and are not independently verified or edited by our team.